<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463265</url>
  </required_header>
  <id_info>
    <org_study_id>GBM007</org_study_id>
    <nct_id>NCT03463265</nct_id>
  </id_info>
  <brief_title>ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma</brief_title>
  <official_title>A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Patients With Recurrent High-grade Glioma and Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aadi, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, open-label study of ABI-009 (nab-Rapamycin) in patients with recurrent high grade&#xD;
      glioma following prior therapy and subjects with newly diagnosed glioblastoma. ABI-009 will&#xD;
      be tested as single agent or in combination with standard therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective overall response rate according to RANO 2010 criteria</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-009 + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-009 + temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-009 + lomustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-009 + temozolomide + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-009 + marizomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009</intervention_name>
    <description>ABI-009 as single agent or in combination with other agents</description>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_label>ABI-009 + bevacizumab</arm_group_label>
    <arm_group_label>ABI-009 + lomustine</arm_group_label>
    <arm_group_label>ABI-009 + marizomib</arm_group_label>
    <arm_group_label>ABI-009 + temozolomide</arm_group_label>
    <arm_group_label>ABI-009 + temozolomide + radiotherapy</arm_group_label>
    <other_name>nab-rapamycin, nanoparticle albumin-bound rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>bevacizumab</description>
    <arm_group_label>ABI-009 + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>temozolomide</description>
    <arm_group_label>ABI-009 + temozolomide</arm_group_label>
    <arm_group_label>ABI-009 + temozolomide + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>lomustine</description>
    <arm_group_label>ABI-009 + lomustine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>radiation</description>
    <arm_group_label>ABI-009 + temozolomide + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marizomib</intervention_name>
    <description>marizomib</description>
    <arm_group_label>ABI-009 + marizomib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Specific for Arm A&#xD;
&#xD;
          1. All subjects must have histologic evidence of high grade glioma (World Health&#xD;
             Organization [WHO] grade 3 or grade 4) and radiographic evidence of recurrence or&#xD;
             disease progression (defined as either a greater than 25% increase in the largest&#xD;
             bi-dimensional product of enhancement, a new enhancing lesion, or a significant&#xD;
             increase in T2 FLAIR). Subjects must have at least 1 measurable lesion by RANO&#xD;
             criteria (≥ 10 mm in 2 perpendicular diameters).&#xD;
&#xD;
          2. Patients must have previously failed a treatment regimen, including radiation and/or&#xD;
             chemotherapy.&#xD;
&#xD;
          3. No prior treatment with mTOR inhibitors.&#xD;
&#xD;
          4. No prior treatment with temozolomide for the treatment of recurrent glioma for&#xD;
             patients entering the ABI-009 + temozolomide cohort.&#xD;
&#xD;
          5. No prior treatment with bevacizumab or any other anti-angiogenic agents, including&#xD;
             sorafenib, sunitinib, axitinib, pazopanib, or cilengitide for the ABI-009 +&#xD;
             bevacizumab arm.&#xD;
&#xD;
          6. No prior treatment with lomustine for the ABI-009 + lomustine arm.&#xD;
&#xD;
          7. No prior treatment with marizomib or any other proteasome inhibitors, including&#xD;
             bortezomib, carfilzomib, or ixazomib, for patients entering the ABI-009 + marizomib&#xD;
             cohort.&#xD;
&#xD;
          8. At least 4 weeks from surgical resection and at least 12 weeks from the end of&#xD;
             radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor&#xD;
             biopsy or new lesion outside of radiation field, or if there are two MRIs confirming&#xD;
             progressive disease that are approximately 4 weeks apart.&#xD;
&#xD;
        Inclusion Criteria Specific for Arm B&#xD;
&#xD;
          1. Histologically confirmed newly diagnosed glioblastoma.&#xD;
&#xD;
          2. Patients must have had surgery and can have either non-measurable disease or a&#xD;
             measurable post-contrast lesion after surgery detected by MRI.&#xD;
&#xD;
          3. No prior treatment with mTOR inhibitors, and no prior local or systemic therapy for&#xD;
             GBM.&#xD;
&#xD;
        Exclusion Criteria Common for Both Arms A and B&#xD;
&#xD;
        A patient will not be eligible for inclusion in this study if any of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Co-medication or concomitant therapy that may interfere with study results, including&#xD;
             anti-coagulants and enzyme-inducing anti-epileptic drugs (EIAEDs).&#xD;
&#xD;
          2. History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.&#xD;
&#xD;
          3. Pregnant or breast feeding.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring IV antibiotics &amp; psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements, or disorders associated with significant&#xD;
             immunocompromised state.&#xD;
&#xD;
          5. Active gastrointestinal bleeding.&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood&#xD;
             pressure ≥90 mm Hg.&#xD;
&#xD;
          7. Patients with history of intestinal perforations, fistula, hemorrhages and/or&#xD;
             hemoptysis ≤6 months prior to first study treatment.&#xD;
&#xD;
          8. Uncontrolled diabetes mellitus as defined by HbA1c &gt;8% despite adequate therapy.&#xD;
&#xD;
          9. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary&#xD;
             hypertension.&#xD;
&#xD;
         10. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving&#xD;
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with&#xD;
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,&#xD;
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to&#xD;
             receiving the first dose of ABI-009.&#xD;
&#xD;
         11. Known other previous/current malignancy requiring treatment within ≤ 3 years except&#xD;
             for limited disease treated with curative intent, such as in situ prostate cancer,&#xD;
             intracapsular renal cancer, cervical carcinoma in situ, squamous or basal cell skin&#xD;
             carcinoma, and superficial bladder carcinoma.&#xD;
&#xD;
         12. Any comorbid condition that restricts the use of study drug and confounds the ability&#xD;
             to interpret data from the study as judged by the Investigator or Medical Monitor.&#xD;
&#xD;
         13. Known Human Immunodeficiency Virus (HIV), or active Hepatitis B or Hepatitis C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

